Richard A. Paulson holds the role of President and CEO at Karyopharm Therapeutics Inc. (KPTI). Paulson's filing history also covers bluebird bio, Inc. (BLUE). Paulson has reported 9 insider filings with the SEC since 2024. The most recent filing was in May 2026.
Every role Richard A. Paulson has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Karyopharm Therapeutics Inc. (KPTI)8 filingsbluebird bio, Inc. (BLUE)1 filingUpdated Aug 31, 2026
Richard A. Paulson is President and CEO of Karyopharm Therapeutics Inc. (KPTI). 9 SEC Form 4 filings on record going back to 2024, most recently on 15 May 2026. Most recent open-market trade: sold $21K of KPTI on 15 May 2026. Lifetime open-market sales: $155K.
Every recent SEC Form 4 transaction Richard A. Paulson has reported, most recent first.
InsiderAlpha's records for Richard A. Paulson go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Richard A. Paulson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Richard A. Paulson is a corporate insider, tracked as President and CEO of Karyopharm Therapeutics Inc. (KPTI). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 15 May 2026, one of 9 filings going back to 2024.
Recorded transactions: 0 open-market purchases and 6 open-market sales ($155K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$KPTI Karyopharm Therapeutics Inc.12.4K shares @ $9.41$116K